logo

Last Update

This profile was last updated on 7/18/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Jonathan Yingling?

Jonathan M. Yingling

Significant Oncology Development Activities

Eli Lilly and Company

Direct Phone: (317) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Eli Lilly and Company

10300 Campus Point Dr.

San Diego, California,92121

United States

Company Description

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true ...more

Background Information

Employment History

Chief Scientific Officer

BIND Therapeutics, Inc


Vice President Discovery Oncology and Translational Research

Bristol-Myers Squibb Company


Senior Vice President

Early Development


Chief Scientific Officer

Angiogenesis & Tumor Microenvironment Biology , Cancer Research


Vice President, Oncology Research

Lilly Research Laboratories


Affiliations

IDERA PHARMACEUTICALS, INC.

Senior Vice President


Vanderbilt University

Howard Hughes Postdoctoral Fellow


Education

Developmental Biology

Vanderbilt University


BS degree

Chemistry

College of William and Mary


PhD

Cell and Molecular Biology and Pharmacology

Duke University


Web References(58 Total References)


Our Team - Idera Pharmaceuticals

www.iderapharma.com [cached]

Jonathan Yingling, Ph.D.
Senior Vice President, Early Development Jonathan Yingling, Ph.D. Senior Vice President, Early Development Jonathan Yingling, Ph.D. Senior Vice President, Early Development close Jonathan Yingling, Ph.D. Senior Vice President, Early Development Dr. Yingling joined the company as Senior Vice President, Early Development in February 2017. Prior to joining Idera, Dr. Yingling was most recently the Chief Scientific Officer of Bind Therapeutics, Inc. Prior to his tenure at Bind Therapeutics, Dr. Yingling served as Vice President of Oncology Discovery and Translational Research at Bristol Myers Squibb and Company. In addition to his tenures at Bind Therapeutics and Bristol Myers Squibb & Company, Dr. Yingling had spent over a decade leading significant oncology development activities as well as drug candidate identification and M&A activities at Eli Lilly and Company. Dr. Yingling received his Ph.D. from Duke University and his Bachelor of Science from the College of William and Mary.


Alexandria Summit: Oncology 2011

alexandriasummit.com [cached]

Jonathan M. Yingling, PhD
Vice President, Oncology Research, Lilly Research Laboratories, Eli Lilly and Company Dr. Yingling received a BS degree in Chemistry from the College of William and Mary in 1990 and was awarded a PhD in Cell and Molecular Biology and Pharmacology from Duke University in 1997. He completed a Postdoctoral Fellowship at Vanderbilt University in Developmental Biology in 1999. He joined Eli Lilly and Company in 2000 as Senior Biologist in the Oncology Division. He was promoted to Chief Scientific Officer, Angiogenesis & Tumor Microenvironment Biology, Cancer Research in 2004. In November 2009 he was named Vice President, Oncology Research, Lilly Research Laboratories. He has driven the PK/PD strategy within Lilly Oncology, which is now a hallmark of the therapeutic area approach. In collaboration with BioTDR/AME, he pioneered several multi-modality therapy projects enabling parallel development of small molecule, antibody and peptide approaches to high-value targets. Most recently he has established key strategic partnerships in the FIPNET environment to execute the patient-tailoring strategy, which is vital to the mission of Lilly Oncology.


Active biotech company shares in the news: Aevi Genomic Medicine, Inc. (NASDAQ:GNMX), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) | Voice Registrar

voiceregistrar.com [cached]

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) on February 6, 2017 announced the appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development.
Dr. Yingling was most recently the Chief Scientific Officer of Bind Therapeutics, Inc., and had previously served as Vice President of Oncology Discovery and Translational Research at Bristol Myers Squibb and Company. In this newly created position, Dr. Yingling will lead and execute the early development strategy and programs necessary to validate further immune-oncology indications for IMO-2125 as well driving the overall third-generation antisense (3GA) platform technology strategy. In addition to his tenures at Bind Therapeutics and Bristol Myers Squibb & Company, Dr. Yingling had spent over a decade leading significant oncology development activities as well as drug candidate identification and M&A activities at Eli Lilly and Company. Dr. Yingling received his Ph.D. from Duke University and his Bachelor of Science from the College of William and Mary.


BIND Management

www.bindtherapeutics.com [cached]

Jonathan Yingling, Ph.D.
Chief Scientific Officer Jonathan Yingling Jonathan Yingling, Ph.D., is our Chief Scientific Officer, having served in this role since joining the Company in December 2015. Prior to joining BIND, Dr. Yingling was vice president, Oncology Discovery and Translational Research at Bristol-Myers Squibb (BMS), where he was responsible for the oncology research portfolio as well as translational capabilities in oncology and immunoscience. While at BMS, Dr. Yingling contributed to the discovery and development of potentially transformative medicines in immuno-oncology and championed several small molecule drug discovery programs including IDO (indoleamine-2,3 dioxygenase), TGF-β and other important intracellular tumor cell targets. He also expanded the biologics portfolio with the addition of FS102, a novel anti-HER2 monoclonal antibody, and several proprietary antibody drug conjugate assets. Dr. Yingling began his pharmaceutical career as a senior biologist in oncology at Eli Lilly & Company, where he served in various positions of increasing responsibility including Chief Scientific Officer of Angiogenesis & Tumor Microenvironment Biology, Vice President of Oncology Research and Vice President of Translational Science and Technology. Dr. Yingling earned his Ph.D. in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University.


www.flagshipventures.com

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer | Flagship Ventures Flagship Ventures VentureLabsVenture Capital Home > Media > BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer BIND Therapeutics, Inc. View Article BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer December 16, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today announced the appointment of Jonathan Yingling, Ph.D., as Chief Scientific Officer. In this position, Dr. Yingling will be responsible for leading BIND's research and development efforts to identify and pursue new product opportunities where the unique attributes of ACCURINs can be leveraged to provide meaningful improvements in patient care. "We are very pleased to welcome Jonathan to our leadership team, where he will significantly enhance our ability to discover and develop novel ACCURIN therapeutics," said Andrew Hirsch, president and chief executive officer, BIND Therapeutics. Dr. Yingling joins BIND from Bristol-Myers Squibb (BMS), where he was vice president, Oncology Discovery and Translational Research. During his tenure at BMS, he was responsible for the oncology research portfolio as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology. He championed several small molecule drug discovery programs including IDO (indoleamine-2,3 dioxygenase), TGF-β and other important intracellular tumor cell targets. He also expanded the biologics portfolio with the addition of FS102, a novel anti-HER2 monoclonal antibody, and several proprietary antibody drug conjugate assets. "I'm excited to join Andrew and the talented team at BIND to utilize my drug discovery and translational science expertise to develop innovative medicines leveraging the ACCURIN platform," said Jonathan Yingling, Ph.D., chief scientific officer at BIND. Dr. Yingling began his pharmaceutical career as a senior biologist in oncology at Eli Lilly & Company in 2000. During his 13-year tenure, he served in various positions of increasing responsibility including CSO of Angiogenesis & Tumor Microenvironment Biology, Vice President Oncology Research; and Vice President of Translational Science and Technology. In those roles, he led innovative drug discovery programs focused on the tumor microenvironment, contributed to the expansion of Lilly's oncology portfolio into targeted therapy and biologics culminating in the acquisition of ImClone in 2008 and integrated tailored therapeutic capabilities across Lilly Research Laboratories. As vice president of Translational Science and Technology, he led target enablement and screening, structural biology, fragment-based drug design and lead optimization biology capabilities across multiple therapeutic areas. Dr. Yingling earned his Ph.D. in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the discovery and development of breakthrough medicines; our expectation that ACCURINs may lead to meaningful improvements in patient care, our ability to expand and develop novel applications for the ACCURIN platform; the ability of Dr. Yingling to successfully execute our strategic vision; our transition into a drug discovery and preclinical development organization; BIND-510, including without limitation the filing of an IND applicable with the U.S. Food and Drug Administration; our collaborations with Pfizer, AstraZeneca, F. Hoffmann-La Roche Ltd., Merck and Macrophage; and upcoming events and presentations. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since its inception and expects to incur losses for the foreseeable future; the Company's need for additional funding, which may not be available; raising additional capital may cause dilution to its stockholders, restrict its operations or require it to relinquish rights to its technologies or drug candidates; the Company's limited operating history; the terms of the Company's credit facility place restrictions on its operating and financial flexibility; failure to use and expand its medicinal nanoengineering platform to build a pipeline of drug candidates and develop marketable drugs; the early stage of the Company's development efforts with only BIND-014 in clinical development; failure of the Company or its collaborators to successfully develop and commercialize drug candidates; clinical drug development involves a lengthy and expensive process, with an uncertain outcome; delays or difficulties in the enrollment of patients in clinical trials; serious adverse or unacceptable side effects or limited efficacy observed during the development of the Company's drug candidates; inability to maintain any of the Company's collaborations, or the failure of these collaborations; the Company's reliance on third parties to conduct its clinical trials and manufacture its drug candidates; the Company's inability to obtain required regulatory approvals; any conclusion by the FDA that BIND-014 does not satisfy the requirements for approval under the Section 505(b)(2) regulatory approval pathway; the fact that a fast track or breakthrough therapy designation by the FDA for the Company's drug candidates may not actually lead to a faster development or regulatory review or approval process; the inability to obtain orphan drug exclusivity for drug candidates; failure to obtain marketing approval in international jurisdictions; any post-marketing restrictions or withdrawals from the market; effects of recently enacted and future legislation; failure to comply with environmental, health and safety laws and regulations; failure to achieve market acceptance by physicians, patients, or third-party payors; failure to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities; effects of substantial competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to retain key executives and attract, retain and motivate qualified personnel; difficulties in managing the Company's growth; risks associated with operating internationally, including the possibility of sanctions with respect to our operations in Russia; the possibility of system failures or security breaches; failure to obtain and maintain patent protection for or otherwise protect our technology and products; effects of patent or other intellectual property lawsuits; the price of our common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company; and any securities class action litigation.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory